Aug 4 (Reuters) - Antibe Therapeutics Inc ATE.V :
* ANTIBE - WOMAC PAIN SCORES CONSTITUTING ATB-346 STUDY'S PRIMARY ENDPOINT SHOWED 44% IMPROVEMENT AT DAY 14 FOR 200 AND 250 MG ONCE-DAILY DOSES
* ANTIBE - WOMAC PAIN SCORES CONSTITUTING ATB-346 STUDY'S PRIMARY ENDPOINT SHOWED 39% IMPROVEMENT AT DAY 14 FOR 150 MG ONCE-DAILY DOSE
* ANTIBE THERAPEUTICS INC - HUMAN PROOF-OF-CONCEPT NOW FIRMLY ESTABLISHED FOR ATB-346
* ANTIBE - STRATEGIC OBJECTIVE IS TO MONETIZE ATB-346 THROUGH PARTNERING ACTIVITY, WHILE EXPEDITIOUSLY MOVING FORWARD WITH PHASE III DEVELOPMENT